NEW YORK (360Dx) – Magnolia Medical Technologies today announced a contract to supply its blood collection device to the US Department of Veterans Affairs hospitals and treatment facilities.
The five-year federal supply schedule contract from the VA is for Magnolia's Steripath Initial Specimen Diversion Device, a mechanical blood culture collection device that the firm said virtually eliminates blood culture contamination, which can result in misdiagnosis of bloodstream infections, including sepsis. According to Magnolia, Steripath has been clinically proven to reduce blood culture contamination by 92 percent with a 12-month sustained contamination rate of .2 percent, resulting in a 97 percent positive predictive value for the diagnosis of bloodstream infections.
According to a company spokesperson, the contract does not have a specific dollar volume commitment.
"Through the efforts of the dedicated healthcare professionals within the VA and [Department of Defense] systems, this patient population will benefit from significant improvements in sepsis testing accuracy, preventing unnecessary antibiotic therapy and the associated risk of developing antibiotic-resistant infections and complications," Magnolia Cofounder and CEO Greg Bullington said in a statement.